Pharmacotherapy, pharmacogenetics and pharmaceutical technology

Summary

Research projects carried out by the group include pharmacokinetic-pharmacodynamic modelling and dose personalisation, the identification of gene polymorphisms as modulators of response and toxicity of the drugs, evaluation of the possible hepatoprotective and immunomodulatory effects of lipid emulsions rich in omega-3 in total parenteral nutrition, the application of nanotechnologies to new drug-administration systems and the research and development of new drug products for pediatric and orphan diseases.

520 Publications

Strategic lines

Populational pharmacokinetic-pharmacodynamic modelling and dose individualization of biologics, antimicrobials and antifungals, and chemotherapeutic drugs: identify predictive factors of exposure variability and exposure-response relationship, predict exposure and response for different dose regimens and redefine dosing strategies to increase the probability of target attainment.

Parenteral nutrition: the influence of omega-3 fatty acid supplements on the inflammatory response in complex high-surgical-risk patients, the protective role of omega-3 fatty acids in total parenteral nutrition-associated liver complications and polymorphisms associated with plasma phytosterols depuration.

Pharmacogenetics: the effect of various genetic polymorphisms on the efficacy and toxicity of treatment with several drugs such as statins, thiopurines, abacavir, tacrolimus, among others.
Pharmaceutical technology: application of nanotechnologies to new drug-administration systems, development of DNA and RNA nanoparticles as potential new agents of drug transfer and development new drugs products for orphan and pediatric diseases.

Selected Publications

Talaveron,JLM;Grande,A;Badosa,EL;Minguet,JB;Marti,JC;Canton,EP;Tahull,MBB, Inflammatory processes involved in the alteration of liver function biomarkers in adult hospitalized patients treated with parenteral nutrition, Front. Nutr., 2023;101034481-1034481, doi:10.3389/fnut.2023.1034481
Rouaz Hajoui,K;García Montoya,E;López Urbano,A;Romero Obon,M;Chiclana Rodríguez,B;Fraschi Nieto,A;Nardi Ricart,A et al, Optimisation of the Manufacturing Process of Organic-Solvent-Free Omeprazole Enteric Pellets for the Paediatric Population: Full Factorial Design, Pharmaceutics, 2023;15(11):doi:10.3390/pharmaceutics15112587
Ronda,M;Padulles,A;Grau,I;Tubau,F;Satorra,P;Shaw,E;Vigues,F et al, Impact of a prospective audit and feedback antimicrobial stewardship programme on carbapenem consumption: a quasi-experimental study (IPANEMA study), J. Antimicrob. Chemother., 2023;78(7):1705-1710, doi:10.1093/jac/dkad160
Martinez Casanova,J;Esteve Pitarch,E;Colom Codina,H;Gumucio Sanguino,VD;Cobo Sacristan,S;Shaw,E;Maisterra Santos,K et al, Predictive Factors of Piperacillin Exposure and the Impact on Target Attainment after Continuous Infusion Administration to Critically Ill Patients, Antibiotics-Basel, 2023;12(3):doi:10.3390/antibiotics12030531
Gonzalez,CGR;de Vega,EC;Martinez,SD;Minero,MV;Urbon,JMG;Manzorro,AG;Martinez,E et al, A critical view on the current use of daptomycin in Spain: The daptomise study, J Infect Public Health, 2023;16(7):1115-1122, doi:10.1016/j.jiph.2023.05.008

Selected Projects

19INT001. Antibiotic plasma level concentrations during continuous renal replacement therapy with a high absorptive membrane (oXiris®). BAXTER HEALTHCARE CORPORATION. Budget: 11.065,26€. 2019-2023. PI: Colom Codina, Helena.
PUB23009. HUB - RECCaracterización de las dislipemias poligénicas: de la teoría a la práctica. Hospital Universitario de Bellvitge. Budget: 20.000€. 2023-2026. PI: Padró i Miquel, Ariadna.
21MAR009. Catalan interhospital network of genetic variants to improve genetic diagnosis in rare diaseases. Fundació La Marató de TV3. Budget: 26.625€. 2021-2024. PI: Padró i Miquel, Ariadna.
19PNJ030. CONTROLES DE CALIDAD DEL ESTUDIO "ESTUDIO DE EVALUACIÓN-VALIDACIÓN DE INMUNOSUPRESORES (EVEROLIMUS Y SIROLIMUS). 2019- . PI: Alía Ramos, Pedro.
2023-593-1. ESTUDIO OBSERVACIONAL PARA EVALUAR LA ADHERENCIA A TREMFYA® (GUSELKUMAB) EN LA PRÁCTICA CLÍNICA EN PACIENTES CON PSORIASIS MODERADA A GRAVE. Janssen-Cilag, S.A. Budget: 10.800€. 2023- . PI: Padullés Zamora, Núria.

More Information

Our IDIBELL research group works in close collaboration with researchers at the School of Pharmacy of the University of Barcelona (Service of Drug Development [SDM] and the Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry. The SDM within the School of Pharmacy collaborates with pharmaceutical and other related industries in the field of Pharmaceutical Technology. Other non-competitive contracts or agreements with companies managed through The Bosch i Gimpera Foundation have been performed by the Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry in the field of Pharmacokinetics.

Patents: Patente de invención (Europea). Título de la invención: Descongestant and bilastine drugs delivery system. Inventores: J.Mª Suñé Negre, M Roig Carreras, F Gual Pujol, P Marcianes, I Ortega Azpitarte, G Hernández Herrrero. Solicitante: FAES FARMA, SA.
Número de registro: EP 20382701.9 (Prioridad XX.XX.2020). Fecha de presentación: 30 de julio de 2020. Lugar de presentación: Canadian Intellectual Property Office.

Doctoral theses directed by a member of the group and read or diposited in 2020: 6 PhD students successfully defended their theses. Active doctoral theses directed by a member of the group: 10 PhD students.

Several members of our group are involved in teaching activities for degrees, Master degrees and specialized courses since 2015. In a proposal of continuous training, members of our team yearly attend to international and national workshops organized by scientific organisms.